U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H16FN7O
Molecular Weight 401.3964
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ACALISIB

SMILES

C[C@H](NC1=C2NC=NC2=NC=N1)C3=NC4=C(C=C(F)C=C4)C(=O)N3C5=CC=CC=C5

InChI

InChIKey=DOCINCLJNAXZQF-LBPRGKRZSA-N
InChI=1S/C21H16FN7O/c1-12(27-19-17-18(24-10-23-17)25-11-26-19)20-28-16-8-7-13(22)9-15(16)21(30)29(20)14-5-3-2-4-6-14/h2-12H,1H3,(H2,23,24,25,26,27)/t12-/m0/s1

HIDE SMILES / InChI
GS-9820 (formerly CAL-120) is an oral, small molecule delta selective Phosphatidylinositol 3-kinases (PI3 kinase) inhibitor, a first in class compound, with greater than 200-fold selectivity in cell-based assays for the delta isoform as compared to other class isoforms. GS-9820 is designed to induce cancer cell death and inhibit signaling pathways associated with cancer cell dependence on the tumor microenvironment. GS-9820 is on the phase I of clinical trial, where has to be determined the appropriate dosing regimen of drug in subjects with lymphoid malignancies.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
12.7 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of isoform-selective phosphatidylinositol 3-kinase inhibitors on osteoclasts: actions on cytoskeletal organization, survival, and resorption.
2013 Dec 6
PI3Kα inhibition reduces obesity in mice.
2016 Nov 4
Patents

Patents

Sample Use Guides

200 mg administered twice a day. Escalation will proceed to the maximum tolerated dose (MTD), defined as the highest tested dose associated with a rate of dose-limiting toxicities (DLT) of < 33% during the first 4 weeks of therapy.
Route of Administration: Oral
GS-9820 (ACALISIB) was characterized using in vitro activity assays in the presence of 10 uM GS-9820. GS-9820 was more selective for PI3Kδ relative to other PI3K class I enzymes (IC50: PI3Kα, 5,441 nm; PI3Kβ, 3,377 nm; PI3Kγ, 1,389 nm; and PI3Kδ, 12.7 nm). GS-9820 was also 103-fold more selective against PI3Kδ than against related kinases, such as CIIβ, hVPS34, DNAPK, and mammalian target of rapamycin.
Name Type Language
ACALISIB
INN   WHO-DD  
INN  
Official Name English
GS-9820
Code English
6-FLUORO-3-PHENYL-2-((1S)-1-(7H-PURIN-6-YLAMINO)ETHYL)QUINAZOLIN-4(3H)-ONE
Systematic Name English
acalisib [INN]
Common Name English
GS9820
Code English
CAL120
Code English
Acalisib [WHO-DD]
Common Name English
CAL-120
Code English
Classification Tree Code System Code
NCI_THESAURUS C129825
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
NCI_THESAURUS C2152
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
Code System Code Type Description
INN
9812
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
PUBCHEM
11618268
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
CAS
870281-34-8
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
SMS_ID
100000175794
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
FDA UNII
OVW60IDW1D
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
DRUG BANK
DB15407
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
NCI_THESAURUS
C103277
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545397
Created by admin on Sat Dec 16 10:31:50 GMT 2023 , Edited by admin on Sat Dec 16 10:31:50 GMT 2023
PRIMARY